Quick Answer
Schizophrenia and psychotic disorders deliver 2-3 NEET PG questions per paper. The high-yield framework:
- Schizophrenia — 2+ symptoms, 1 month active, 6 months total; one must be delusion, hallucination, or disorganised speech.
- Schizophreniform — same as schizophrenia but 1-6 month duration.
- Brief psychotic disorder — <1 month, often post-stressor, full recovery.
- Schizoaffective — psychosis + mood episode, with 2+ weeks of pure psychosis.
- First-line treatment — atypical antipsychotics (risperidone, olanzapine, aripiprazole).
- Clozapine — for treatment resistance or suicidality; mandatory CBC monitoring.
- Drug emergencies — acute dystonia (anticholinergic), NMS (dantrolene + bromocriptine), serotonin syndrome (cyproheptadine), tardive dyskinesia (valbenazine).
Schizophrenia is the prototype psychotic disorder — a disabling lifelong illness with strong genetic loading, characteristic prodrome, and a distinctive medication side-effect profile that examiners enjoy testing in side-by-side stem-and-distractor format. NEET PG questions cluster around DSM-5 diagnostic boundaries, antipsychotic-specific adverse effects, and the medical emergencies (NMS, dystonia, agranulocytosis) that demand urgent recognition.
This NEETPGAI guide walks through the schizophrenia spectrum, antipsychotic pharmacology and selection, extrapyramidal syndromes, NMS, and clozapine monitoring — with a focus on the "which drug, which side effect, which antidote" patterns examiners reuse year after year. Pair this with the Psychiatry hub and the mood disorders deep dive for full psychiatric coverage.
Schizophrenia DSM-5 — the diagnostic backbone
Schizophrenia requires 2 or more of the following Criterion A symptoms, present for a significant portion of time during a 1-month active phase, with continuous signs of disturbance for 6 months total (including prodromal and residual phases):
- Delusions
- Hallucinations
- Disorganised speech (loose associations, tangentiality, word salad)
- Grossly disorganised or catatonic behaviour
- Negative symptoms (avolition, alogia, anhedonia, asociality, affective flattening)
At least one of the first three must be present. Significant social or occupational dysfunction is required, and schizoaffective, mood, and substance-induced causes must be excluded.
Positive vs negative symptoms
| Type | Examples | Response to antipsychotics |
|---|
| Positive | Delusions (persecutory, grandiose, somatic), hallucinations (auditory most common), disorganised speech and behaviour | Strong response — dopamine D2 blockade |
| Negative | Affective flattening, alogia, avolition, anhedonia, asociality, attention deficit | Modest response — partial benefit from atypicals (clozapine, cariprazine) |
| Cognitive | Attention, working memory, executive function deficits | Limited response; functional impact often largest |
Subtypes — abolished in DSM-5
The classical paranoid, disorganised, catatonic, undifferentiated, and residual subtypes are no longer used in DSM-5. Instead, dimensional severity ratings are applied. NEET PG examiners may still reference the old subtypes — recognise them but answer DSM-5 framing.
The schizophrenia spectrum — duration is the discriminator
| Disorder | Duration | Key features |
|---|
| Brief psychotic disorder | At least 1 day, <1 month | Often post-stressor, postpartum onset possible, full return to premorbid function |
| Schizophreniform disorder | 1-6 months | Same Criterion A as schizophrenia; functional decline NOT required |
| Schizophrenia | 6 months or more | Functional decline required |
| Schizoaffective disorder | Lifelong | Concurrent mood episode + 2+ weeks pure psychosis; mood symptoms present majority of time |
| Delusional disorder | At least 1 month | Single non-bizarre delusion; functioning otherwise preserved; subtypes erotomanic, grandiose, jealous, persecutory, somatic |
| Shared psychotic disorder (folie à deux) | Variable | Delusion shared between two close individuals; removed as separate diagnosis in DSM-5 but still exam-tested |
Schizoaffective vs MDD with psychotic features
This is a classic NEET PG trap. In schizoaffective, psychotic symptoms must be present for at least 2 weeks without prominent mood symptoms, and mood episodes must be present for the majority of total illness duration. In MDD with psychotic features or bipolar with psychotic features, psychotic symptoms occur only during the mood episode.
Epidemiology and risk factors
- Lifetime prevalence: roughly 1% globally and in India.
- Age of onset: late teens to early 30s. Earlier onset in males (15-25) than females (25-35).
- Risk factors: family history (heritability ~80%), advanced paternal age, obstetric complications, urban birth, winter/spring birth, cannabis use in adolescence, first- or second-generation migrant status.
- Course: prodromal → active → residual. Approximately 1/3 recover, 1/3 have intermittent course, 1/3 chronically ill.
Antipsychotic pharmacology
First-generation (typical) antipsychotics
Block D2 receptors. High-potency (haloperidol, fluphenazine, trifluoperazine) cause more extrapyramidal symptoms but less sedation/anticholinergic effects. Low-potency (chlorpromazine, thioridazine) cause more sedation, postural hypotension, anticholinergic effects but fewer EPS.
- Haloperidol — workhorse for acute psychosis and delirium. Available IM depot (haloperidol decanoate).
- Chlorpromazine — high antihistamine, sedating; classic NEET PG side-effect cluster includes corneal/lens deposits, photosensitivity, cholestatic jaundice.
- Thioridazine — retinal pigmentation, QT prolongation; rarely used now.
Second-generation (atypical) antipsychotics
Block D2 + 5-HT2A receptors. Lower EPS risk, but higher metabolic side effects. First-line for schizophrenia.
- Risperidone — most prolactin elevation among atypicals; depot available.
- Olanzapine — best efficacy after clozapine but highest weight gain and metabolic burden.
- Quetiapine — sedating, used for sleep and bipolar depression; minimal EPS.
- Aripiprazole — partial D2 agonist; weight neutral; akathisia common.
- Ziprasidone, lurasidone — weight neutral; lurasidone preferred for bipolar depression.
- Cariprazine, brexpiprazole — newer partial agonists; cariprazine has signal for negative symptoms.
- Paliperidone — active metabolite of risperidone; long-acting injectables (1-month, 3-month, 6-month formulations).
Clozapine — the gold standard for resistance
Only antipsychotic shown to reduce suicidality in schizophrenia. Reserved for:
- Treatment-resistant schizophrenia (failure of 2 adequate trials of different antipsychotics, each at adequate dose for 6+ weeks)
- Persistent suicidal behaviour in schizophrenia or schizoaffective disorder
- Tardive dyskinesia
- Refractory psychosis in Parkinson disease (low-dose clozapine)
Mandatory monitoring:
- Weekly CBC × 18 weeks
- Biweekly CBC weeks 19-52
- Monthly CBC thereafter
- Stop if absolute neutrophil count drops below 1500/µL
- ECG, troponin, CRP at baseline and during titration (myocarditis risk peaks 4-6 weeks)
Adverse effects: agranulocytosis (~0.8%), myocarditis, seizures (dose-dependent, >600 mg/day), hypersalivation (paradoxical), constipation (severe — fatal ileus reported), weight gain, metabolic syndrome, orthostatic hypotension during titration.
Extrapyramidal syndromes — recognise and time
| Syndrome | Onset | Features | Treatment |
|---|
| Acute dystonia | Hours to days | Sustained painful muscle contraction — oculogyric crisis, torticollis, opisthotonus, laryngospasm | IM/IV anticholinergic (benztropine, diphenhydramine, promethazine) |
| Akathisia | Days to weeks | Subjective restlessness, inability to sit still, dysphoria | Reduce dose, beta-blocker (propranolol), benzodiazepine, switch to lower-EPS agent |
| Parkinsonism | Weeks to months | Tremor, rigidity, bradykinesia, masked facies | Anticholinergic (trihexyphenidyl) or amantadine; dose reduction |
| Tardive dyskinesia | Months to years | Repetitive choreoathetoid movements of face, tongue, limbs; often irreversible | VMAT2 inhibitors (valbenazine, deutetrabenazine); switch to clozapine; never use anticholinergic — worsens TD |
| Tardive dystonia | Months to years | Sustained dystonic posturing, often retrocollis | Clozapine, valbenazine; botulinum toxin for focal forms |
Neuroleptic malignant syndrome — the antipsychotic emergency
NMS is a rare but life-threatening idiosyncratic reaction (incidence 0.02-3%). Mortality 10-20% if untreated.
Diagnostic tetrad
- Hyperthermia (often >38.5°C, can reach 41°C+)
- Lead-pipe muscle rigidity
- Altered mental status (delirium, stupor, coma)
- Autonomic instability (labile BP, tachycardia, diaphoresis, dysrhythmia)
Lab findings
- CK markedly elevated (often >1000 U/L)
- Leukocytosis (10,000-40,000)
- Metabolic acidosis
- AKI from rhabdomyolysis
- Transaminitis
Management
- Stop the offending antipsychotic immediately.
- Aggressive cooling (cooling blankets, IV cold fluids).
- Hydration and electrolyte correction; alkalinise urine if rhabdomyolysis.
- Dantrolene 1-2.5 mg/kg IV every 6 hr (skeletal muscle relaxant — same drug as malignant hyperthermia).
- Bromocriptine 2.5-5 mg PO every 8 hr (dopamine agonist — restores central dopamine tone).
- ICU monitoring; benzodiazepines for severe agitation.
- ECT if refractory after 5-7 days.
- Re-challenge with a different antipsychotic, preferably atypical, after 2+ weeks recovery.
NMS vs serotonin syndrome — exam favourite
| Feature | NMS | Serotonin syndrome |
|---|
| Triggering drug | Antipsychotics (D2 blockade) | SSRIs, SNRIs, MAOIs, tramadol, linezolid |
| Onset | Days to weeks | Hours |
| Muscle tone | Lead-pipe rigidity, hyporeflexia | Hyperreflexia, clonus (lower limbs > upper) |
| Pupils | Normal or miotic | Mydriasis |
| Bowel sounds | Decreased | Hyperactive |
| Antidote | Dantrolene + bromocriptine | Cyproheptadine |
Suicide and violence in schizophrenia
- Lifetime suicide risk: approximately 5%. Highest in young males, early in illness, post-discharge, with insight into illness, comorbid depression.
- Violence: Risk modestly increased above population baseline; concentrated in those with substance comorbidity and active psychotic symptoms.
- Clozapine is the only antipsychotic with FDA indication for suicide reduction in schizophrenia and schizoaffective disorder.
High-yield NEET PG MCQ traps
- First-rank symptoms of Schneider (audible thoughts, voices arguing, voices commenting, somatic passivity, thought withdrawal/insertion/broadcasting, made will/affect/impulse, delusional perception) — historically pathognomonic for schizophrenia, now with reduced specificity in DSM-5.
- Capgras syndrome — delusion that a loved one has been replaced by an impostor.
- Fregoli syndrome — different people are believed to be a single persecutor in disguise.
- Cotard syndrome — nihilistic delusion of being dead or non-existent (psychotic depression > schizophrenia).
- De Clerambault (erotomania) — delusion that someone famous or higher-status is in love with the patient.
- Folie à deux — shared delusion between two closely associated persons.
- Lewy body psychosis — never give typical antipsychotics; severe sensitivity reactions. Use quetiapine or clozapine in low dose.
- Antipsychotics in pregnancy — haloperidol and olanzapine have most safety data; first-generation generally preferred.
- Hyperprolactinaemia ranking — risperidone > haloperidol >> olanzapine >> aripiprazole (often lowers prolactin).
- Metabolic syndrome ranking — clozapine > olanzapine >> quetiapine > risperidone >> aripiprazole > ziprasidone > lurasidone.
Recent updates
- Lumateperone — novel atypical with serotonin/dopamine/glutamate modulation; FDA-approved for schizophrenia and bipolar depression.
- Xanomeline-trospium (Cobenfy) — muscarinic agonist FDA-approved 2024 — first non-D2 mechanism antipsychotic in 70 years.
- Long-acting injectables (LAIs) — paliperidone palmitate 6-monthly LAI improves adherence; preferred for first-episode patients in many guidelines.
- Indian context: schizophrenia covered under National Mental Health Programme; District Mental Health Programme dispenses olanzapine, risperidone, haloperidol free in most districts. The Mental Healthcare Act 2017 mandates supported admission with nominated representative consent — an FMGE/NEET PG legal-medicine cross-question.
Frequently asked questions
What are the DSM-5 criteria for schizophrenia?
Two or more of: delusions, hallucinations, disorganised speech, grossly disorganised or catatonic behaviour, or negative symptoms — for at least 1 month of active symptoms within a 6-month period of disturbance. At least one symptom must be from the first three. Significant social/occupational dysfunction is required, with mood and substance causes excluded.
How do you distinguish schizoaffective from schizophrenia?
Schizoaffective disorder requires major mood episode (depression or mania) concurrent with psychotic symptoms, plus at least 2 weeks of psychosis without prominent mood symptoms. Mood symptoms must be present for the majority of total illness duration. Schizophrenia has minimal mood pathology, while mood disorder with psychosis lacks the standalone-psychosis phase.
What is neuroleptic malignant syndrome and how is it treated?
NMS is a life-threatening reaction to antipsychotics — fever, lead-pipe rigidity, autonomic instability, altered mental status, elevated CK and leukocytosis. Stop the offending drug, give aggressive cooling, IV fluids, and dantrolene 1-2.5 mg/kg IV or bromocriptine 2.5 mg every 8 hr. Mortality 10-20% if untreated.
When is clozapine indicated and what monitoring is required?
Clozapine is reserved for treatment-resistant schizophrenia (failure of 2+ adequate antipsychotic trials) and persistent suicidality. Mandatory weekly CBC for 18 weeks then biweekly to 12 months then monthly — neutropenia and agranulocytosis risk 0.8%. Also monitor for myocarditis, seizures, hypersalivation, and metabolic syndrome.
What is the difference between tardive dyskinesia and acute dystonia?
Acute dystonia occurs within hours-days of starting an antipsychotic — sustained painful muscle contractions like oculogyric crisis or torticollis. Treated with anticholinergic IV. Tardive dyskinesia appears after months-years of antipsychotic use — irreversible repetitive choreoathetoid movements of face and tongue. VMAT2 inhibitors (valbenazine, deutetrabenazine) are the only approved treatments.
This content is for educational purposes for NEET PG exam preparation. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical information has been reviewed by qualified medical professionals.
Written by: NEETPGAI Editorial Team
Reviewed by: Pending SME Review
Last reviewed: April 2026
